57th ERA-EDTA Congress Abstracts

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10591 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

57th ERA-EDTA Congress Abstracts

posted on Jun 08, 2020 05:04AM

Recap:

Page 102

ASPECTS OF CKD PATHOPHYSIOLOGY1

APABETALONE, A BROMODOMAIN AND EXTRA-TERMINAL(BET) PROTEIN INHIBITOR, REDUCES ALKALINE PHOSPHATASE IN CVD PATIENTS, IN MICE, AND IN CELL CULTURE SYSTEMS

Conclusion: Apabetalone lowers serum ALP in clinical trials, which is consistent with reduced hepatic production of TNALP - the most abundant ALP isoform. Further, apa-betalone downregulatesALPLgene expression in vascular cell types while reducing calcification. Together, BET-dependent epigenetic modulation of ALP by apabetalone can affect several pathogenetic processes, and thereby improve cardiovascular outcomes. This study provides insights to the CVD event reductions observed in the CKD subpopulation in the BETonMACE Phase 3 trial.

Page 200

CARDIOVASCULAR AND RENAL PROTECTION-EFFECTS OF SGLT2INHIBITORS AND GLP-1RECEPTOR AGONISTS IN PEOPLE WITH CKD ANDTYPE2DIABETES

EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT.

Conclusion: Patients with T2D, ACS, and Stage 3 CKD have a very high risk of subsequent MACE plus CHF hospitalization. The BET protein inhibitor ABP may reduce this risk.

Page 382

APABETALONE, A CLINICAL STAGE BET INHIBITOR, REDUCES THE PRO-INFLAMMATORY RESPONSE IN PBMCSFROM FABRY DISEASE PATIENTS ON ERT THERAPY

Conclusion: Monocytes from FD patients on ERT therapy display an enhanced expression of the CCR2-MCP-1 axis as compared to naı ̈ve controls, indicating the potential for immune cell tissue infiltration and local inflammation. Apabetalone counters this increase by preventingMCP1gene transcription. Apabetalone also reduces PBMCmediated pro-inflammatory gene transcription (TNFA, IL12B, IL6) and neutrophil-mediated ROS production in response to LPS stimulation. Therefore, apabetalone treatment may reduce pathological inflammation in FD patients and thus complementERT to optimize patient outcomes, which will be tested further with warranted clinical studies.